Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics announced positive Phase 3 HAELO trial results for lonvo-z, a CRISPR gene-editing treatment for hereditary angioedema (HAE). The treatment achieved an 87% reduction in monthly attacks versus placebo, with 62% of patients attack-free during the evaluation period. The company initiated a rolling BLA submission with the FDA and expects U.S. approval and launch in the first half of 2027.